Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals, Inc. reaffirmed its previously announced financial guidance for the fiscal year ending December 31, 2026. The outlook remains unchanged from the financial guidance communicated on April 29, 2026 in its first quarter 2026 earnings release.
The company characterizes these expectations as forward-looking statements that involve risks and uncertainties related to discovering, developing and commercializing human therapeutics and building a business around them. It notes that actual results could differ materially if underlying assumptions do not materialize, and directs readers to its annual report for the year ended December 31, 2025 and its most recent quarterly report for a more detailed description of risks.
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett reported insider transactions involving company stock. On July 7, he executed open-market sales of 15,000 shares held indirectly through a trust at a weighted average price of $85.462 per share and 5,536 shares held directly at a weighted average price of $83.579 per share, under a pre-arranged Rule 10b5-1 trading plan. He also transferred 15,000 shares from direct to indirect ownership via a family trust and reported 15,000 restricted stock units that vested on January 15, 2026 and were paid in common shares. Following these transactions, he holds 75,018 shares directly, 15,000 shares indirectly through the trust, and 12,109 restricted stock units.
Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares. On July 7, 2026, Diaz exercised a non-qualified stock option to acquire 10,111 shares of common stock at $47.11 per share, then sold 10,111 shares in open-market transactions at a weighted average price of $85.4156 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Diaz directly owned 3,811 shares of Ionis common stock.
IONIS PHARMACEUTICALS INC EVP and Chief Development Officer Holly B. Kordasiewicz sold 362 shares of common stock in an open-market transaction at $84.30 per share on July 7, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, and she now holds 22,096 shares directly.
Ionis Pharmaceuticals reported that the CARDIO-TTRansform Phase 3 trial of eplontersen in transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, a composite of cardiovascular death and recurrent cardiovascular events through Week 140 versus placebo.
In patients receiving contemporary standard of care, including many on TTR stabilizers, adding eplontersen did not show a statistically significant benefit on this main outcome. A prespecified subgroup on eplontersen monotherapy showed a nominally significant hazard ratio of 0.71 for the same composite. Secondary imaging and biomarker measures generally favored eplontersen, and the drug showed large, sustained reductions in transthyretin with a safety profile consistent with prior studies. Ionis and AstraZeneca plan to present full results at the European Society of Cardiology Congress in August 2026.
IONS insider filing for proposed sale of 60,846 shares. The filing shows a proposed disposition by Holly Kordasiewicz of 60,846 shares of Common Stock dated 06/12/2026 with an aggregate value of $4,466,425. The securities were originally granted as Restricted Stock on 01/15/2021.
IONS submitted a Form 144 notice dated 07/07/2026 reporting an intended sale of 67,386 shares of Common Stock on Nasdaq. The filing lists 20,536 as Owned Shares (01/15/2020) and 46,850 tied to a Stock Option Exercise (01/04/2021), with the broker noted as Stifel Nicolaus.
IONIS PHARMACEUTICALS INC director Michael J. Yang received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units tied to common stock and 5,369 non-qualified stock options with an exercise price of $79.19 per share.
Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholders’ meeting. The RSU delivery is deferred until the earlier of the fifth anniversary of vesting, a qualifying separation from service, or a change in control. After these grants, Yang directly holds 9,451 RSU-based common shares and 5,369 options. The company notes his 2026 annual equity compensation was adjusted to total no more than $400,000 in grant date fair value under its non-employee director policy.
IONIS PHARMACEUTICALS INC director Joseph Loscalzo received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of common stock or its cash equivalent, bringing his RSU-related holdings to 7,521 units.
He was also granted 5,369 Non-Qualified Stock Options with an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next annual stockholders’ meeting, with RSUs delivered on the July 15 following vesting. The company’s Non-Employee Director Compensation Policy caps his 2026 annual equity compensation at $400,000 based on grant date fair value under FASB Topic ASC 718.